Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
52-week range
$0.00 – $0.00
0% from low
Borrow rate
31.99%
Hard to borrow
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | |
|---|---|---|---|---|---|---|---|
| Revenue | $6.5M | $13.1M | $15.1M | $22.1M | $2.8M | $2.2M | $4.8M |
| Cost of revenue | $7.4M | $10.5M | $12.9M | $15.7M | $6.3M | $6.9M | $7.7M |
| Gross profit | −$914.3K | $2.6M | $2.2M | $6.4M | −$3.6M | −$4.7M | −$2.9M |
| Gross margin | -14.1% | 19.8% | 14.5% | 29.1% | -127.9% | -211.1% | -60.9% |
| R&D | $9.7M | $7.5M | $19.7M | $11.0M | $8.0M | $11.3M | $10.4M |
| Operating income | −$25.2M | −$24.7M | −$40.4M | −$30.0M | −$31.7M | −$32.1M | −$25.1M |
| EBITDA | −$21.3M | −$22.6M | −$37.0M | −$25.1M | −$33.5M | −$30.6M | −$23.6M |
| Net income | −$19.4M | −$25.5M | −$39.0M | −$27.5M | −$49.4M | −$45.8M | −$26.5M |
| Net margin | -300.2% | -195.4% | -258.6% | -124.4% | -1778.8% | -2074.9% | -556.7% |
| EPS (diluted) | -77.75 | -63.06 | -69.86 | -36.16 | -44.57 | -22.25 | -12.37 |
Annual figures · source: Financial Modeling Prep
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $29M | $-0.17 | $-0.17–$-0.17 | 1 |
| 2027 | $50M | $0.18 | $0.18–$0.18 | 1 |
Forward consensus · source: Financial Modeling Prep
No one on the platform currently holds DMKPQ.
No tracked institution reports a position in DMKPQ as of their last filing.
No one on the platform has traded DMKPQ yet.
| +0.00% |
| $107 |
| — |
| EFTReFFECTOR Therapeutics, Inc. | $0.00 | +0.00% | $2823 | — |
| IMVIFIMV Inc. | $0.00 | +0.00% | $23423 | — |
Source: Financial Modeling Prep · peers by sector/industry
No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.
$DMKPQ If it's game over and we were wiped out, why our offline shares still not removed by brokers?
View on StockTwits ↗$DMKPQ This is what I thought then and asked AI. Thanks AI: DMK Pharmaceuticals (formerly Adamis Pharmaceuticals) faced an operational and legal deadlock that made a quick pivot nearly impossible. They couldn't simply "walk away" earlier due to exclusive contractual obligations, lack of liquidity, and the technical complexity of pharmaceutical manufacturing. Here are the main reasons why they waited until the Chapter 11 filing to take legal action: 1. Contractual Constraints and "Lock-in" Exclusivity Agreements: DMK had exclusive commercialization deals with US WorldMeds (USWM) for key products like the Zimhi nasal spray. Unilaterally breaking these contracts would have exposed the company to massive penalties and immediate legal battles they couldn't afford. Long-term Contracts with Catalent: The supply agreement with Catalent for the Symjepi product dated back to 2015 and had been automatically extended, tying DMK to a single manufacturer for years.
View on StockTwits ↗$DMKPQ Transcript regarding Hearing Held 1/20/2026 RE: Rule 16 Conference. Remote electronic access to the transcript is restricted until 5/4/2026. The transcript may be viewed at the Bankruptcy Court Clerk's Office. For information about how to obtain a transcript, call the Clerk's Office or Contact the Court Reporter/Transcriber, Reliable, at Telephone number 302-654-8080. Filed by Reliable Companies . Notice of Intent to Request Redaction Deadline Due By 2/9/2026. https://cases.creditorinfo.com/dmk/documents/docket
View on StockTwits ↗$DMKPQ Unbelievable, after all these days, nothing. 🤦🏻
View on StockTwits ↗@Yeueehehe Can you explain why you haven’t checked on @TDC1 yet?! the mans riddled with HIV AIDS and you hate him for it!!! $DMKPQ for life!!!
View on StockTwits ↗Recent $TICKER stream from stocktwits.com — refreshed every 5 minutes. Sentiment tags are self-reported by posters. Not investment advice.